A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma

Matthew C. Hynes1,2, Paul Nguyen3, Patti A. Groome4, Yuka Asai1,5, Meaghan E. Mavor4, Tara D. Baetz1,6 and Timothy P. Hanna1,3,4,6*

Abstract
Background: The 8th edition UICC/AJCC TNM8 (Tumour, Nodes, Metastasis) melanoma staging system introduced several modifications from the 7th edition (TNM7), resulting in changes in survival and subgroup composition. We set out to address the limited validation of TNM8 (stages I-IV) in large population-based datasets.

Methods: This retrospective cohort-study included 6,414 patients from the population-based Ontario Cancer Registry diagnosed with cutaneous melanoma between January 1, 2007 and December 31, 2012. Kaplan–Meier curves estimated the melanoma-specific survival (MSS) and overall survival (OS). Cox proportional hazard models were used to estimate adjusted hazard ratios for MSS and OS across stage groups. The Schemper-Henderson measure was used to assess the variance explained in the Cox regression.

Results: In our sample, 21.3% of patients were reclassified with TNM8 from TNM7; reclassifications in stage II were uncommon, and 44.1% of patients in stage III were reclassified to a higher subgroup. Minimal changes in MSS curves were observed between editions, but the stage IIB curve decreased and the stage IIIC curve increased. For TNM8, Stage I (n = 4,556), II (n = 1,206), III (n = 598), and IV (n = 54) had an estimated 5-year MSS of 98.4%, 82.5%, 66.4%, and 14.4%, respectively. Within stage III, IIIA 5-year MSS was 91.7% while stage IIID was 23.5%. HRs indicated that TNM8 more evenly separates subgroups once adjusted for patient- and disease-characteristics. The variance in MSS explained by TNM7 and TNM8 is 18.9% and 19.7%, respectively.

Conclusion: TNM8 performed well in our sample, with more even separation of stage subgroups and a modest improvement in predictive ability compared to TNM7.

Keywords: Melanoma, Skin neoplasms, Neoplasm staging, Ontario, Survival analysis, Prognosis, Cohort studies

Introduction
Melanoma is the eighth most common cancer among Canadians with an estimated 7,800 new cases in 2019 [1]. Melanoma is the most fatal form of skin cancer, and
Node, Metastasis) system. Within T categories, Breslow thickness measurements are recorded to one decimal place, T1a and T1b are redefined, and mitotic rate is no longer a staging criterion. Within N categories, there is further stratification by the number of tumor-involved lymph nodes. The eighth edition also introduced a fourth stage III subgrouping (IIID) and restructured the T and N combinations of each respective stage III subgroup [4]. TNM8 refers to the 8th edition staging criteria for melanoma shared by AJCC8 and UICC8.

Changes to the AJCC/UICC staging system were made following the creation and analysis of the International Melanoma Database and Discovery Platform (IMDDP). The IMDDP is an institutional series including >46,000 patients with stage I-III cutaneous melanoma from five countries (Australia, Greece, Italy, Spain, U.S.A.). The resulting TNM8 changes demonstrated superior separation of stage subgroup Kaplan–Meier curves and a 15–29 percentile point increase in survival for stages IIIA/B/C [4].

The majority of previous TNM8 validation studies are institutional series [6–13]. Large population-based studies evaluating the performance of the entire TNM8 (stages I-IV) are lacking. These are important to represent the full spectrum of patients with melanoma. For example, age distribution or the presence of important pathologic prognostic factors such as ulceration may not be adequately represented in institutional populations. Moreover, treatments outside of highly-specialized tertiary care centres may vary, affecting melanoma-specific survival [6, 7, 12].

In this paper, we assess the 8th edition UICC/AJCC (TNM8) staging system for cutaneous melanoma in a Canadian population-based sample using the Ontario Cancer Registry. We detail the extent of subgroup reclassification, changes to stage-specific MSS and OS, adjusted hazard ratios across stage groups, and the amount of survival variance explained by TNM8.

Materials & methods

Data sources and linkage

Data utilized in this study were obtained from administrative datasets at ICES. ICES, formerly known as the Institute for Clinical Evaluative Sciences, is an independent, non-profit research institute funded by an annual grant from the Ontario Ministry of Health and the Ministry of Long-Term Care. As a prescribed entity under Ontario’s privacy legislation, ICES is authorized to collect and use health care data for the purposes of health system analysis, evaluation, and decision support. Secure access to these data is governed by policies and procedures that are approved by the Information and Privacy Commissioner of Ontario. All personal identifying information is removed at ICES, and an anonymous unique identifier, the ICES Key Number (IKN), is generated for each patient.

The Ontario Cancer Registry (OCR) is a population-based tumor registry administered by Cancer Care Ontario (CCO). The OCR captures >95% of newly diagnosed cutaneous melanoma in Ontario, Canada [14, 15]. The OCR passively collects cancer data on the >14 million residents of Ontario through pathology reporting, hospital records, CCO treatment centres, and death records. The OCR records diagnostic information required for staging. Demographic information, including date of birth, sex, and address, was obtained from the Registered Persons Database (RPDB), a repository for all Ontario residents who are eligible for Ontario Health Insurance Plan (OHIP). All information on all deaths, including the cause of death, registered in Ontario is provided by the Office of the Registrar General-Deaths (ORGD) data. Records of acute hospital inpatient and day surgery admissions and discharges were collected from the Canadian Institute for Health Information Discharge Abstract Database and Same Day Surgery (CIHI DAD and SDS) data. Records of radiation and systemic therapy were collected within Activity Level Reporting (ALR) data. Records of intravenous drugs approved for delivery in Ontario were documented in the New Drug Funding Program (NDFP) and drug benefits for all adults aged 65+ and those receiving social assistance were collected from the Ontario Drug Benefit (ODB) program. These datasets were linked using unique encoded identifiers and analyzed at ICES.

Patient selection

A retrospective population-based cohort was derived from a 65% random sample of cutaneous melanoma recorded in the OCR and diagnosed between January 1, 2007 and December 31, 2012. The 65% random sample was a convenience sample, with the sample size calculated for the power requirements of the parent study investigating melanoma treatment outcomes according to stage [16–18]. Eligible participants were residents of Ontario, >19 years in age, diagnosed with invasive cutaneous melanoma, and had no previous history or concurrent cancer (Fig. 1). Patients were followed up to 5 years from diagnosis, or until death, whichever occurred first.

Regarding disease characteristics, patients were excluded for prior or concurrent cancer diagnosis, in situ melanoma at first diagnosis, and core/FNA biopsies only, due to concerns of confounding disease, incomplete OCR reporting, and inaccurate staging, respectively. To preserve data accuracy, patients were excluded for missing pathology records, unreliable pathology records, lapses in OHIP coverage within 5-years of diagnosis, non-valid...
Pathology database with a 65% random sample of invasive cutaneous melanoma cases diagnosed in Ontario in January 2007-December 2012
N=9,212 patients (9,802 cases)

Non-applicable or unreliable pathology records
N=76 patients (79 cases)

Non-valid IKNs in ICES OCR database
N=259 patients (261 cases)

Linkage with ICES Ontario Cancer Registry (OCR)
N=8,877 patients (9,462 cases)

Missing pathology records at first diagnosis
N=438 patients

In situ melanoma cases at first diagnosis
N=386 patients

Core/FNA only biopsies at first diagnosis
N=8 patients

Complete staging data for first primary diagnosis
N=8,045 patients

Mismatches in age and sex, 19 years or younger, and out-of-province residents
N=102 patients

Prior or concurrent history of cancer from diagnosis
N=1,276 patients

Lapses in OHIP coverage in a 5-year window from diagnosis
N=253 patients

Melanoma pathology platform
N=6,414 patients

Fig. 1 Identification of invasive cutaneous melanoma patients and their pathology records in Ontario from January 1, 2007 to December 31, 2012
IKN in the OCR, and demographic incompatibility. This study was approved by the Queen's University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board (EPID-425–13). This study followed the Strengthening the Reporting of Observational Studies in Epidemiology reporting guideline for cohort studies.

Classification of independent variables
Data on the following disease characteristics were collected: histological subtype, Breslow thickness, mitotic rate, ulceration, location, and other attributes required for TNM staging (Table 1). Patients were staged according to the TNM 7th edition (TNM7) and TNM8 criteria and combinations. For the T-category, “missing” ulceration results were treated as “absent” ulceration to provide the minimal staging information. Age and sex were determined from the RPDB. Area-level income quintiles were determined based on quintile rankings of neighbourhood average income within each census metropolitan area or census agglomeration. Rurality was measured with the 2008 Rurality Index for Ontario (RIO) scale, ranging from 0 to 100, and categorised as urban (RIO < 10), suburban (10 ≤ RIO < 40), and rural (RIO ≥ 40). Comorbidity was based on the Elixhauser comorbidity index using CIHI DAD and SDS data with a 5-year lookback from diagnosis. Adjuvant and palliative-intent systemic therapy was measured using ALR, NDFP, and ODB data from 1-year following diagnosis. Radiation treatment was also based on ALR data within 1-year following diagnosis.

Classification of dependant variables
Cause-of-death information was available up to December 31, 2017. Therefore, complete follow-up to death or five years was available for all included patients. Melanoma-specific survival (MSS) and overall survival (OS) were measured up to 5 years from the date of diagnosis, or until death, if the event had occurred earlier. A five-year cut-off was chosen to avoid bias associated with incomplete follow-up to 10 years for most of the cohort. MSS captured underlying deaths due to melanoma defined with ICD-10 diagnosis code ‘C43’ in the ORGD data while OS captured all causes of death.

Statistical analysis
Kaplan–Meier methods were first used to generate the MSS and OS estimates and pointwise 95% confidence limits by the stage groups. Log-rank tests were used to evaluate the differences of MSS and OS amongst the stage groups. Then, Cox proportional hazard regression analyses were performed with adjustments of the stage group hazard ratios for patient and disease factors. The Schemper-Henderson measure was used to calculate the percent of the variance explained by stage in the Cox regression, which allowed data from censored participants to be used in the assessment of cure prediction [19–21]. For our analyses, two-sided statistical significance was determined using a p-value < 0.05.

Statistical analyses were conducted using the SAS software version 9.4 (SAS Institute Inc., Cary, NC).

Results
Baseline characteristics
Of the 9,212 patients initially selected, 2,798 were excluded; patients were most often excluded for prior or concurrent cancer diagnosis (1,276), missing pathology records (438), and in situ melanoma at first diagnosis (386) (Fig. 1). In total, 6,414 patients met the inclusion criteria for analysis. The median age at diagnosis was 61 years (interquartile range [IQR] 49–73) and just over half of the patients were male (51.7%). The most common subtypes of melanoma were superficial spreading (41.9%) and unspecified (31.8%). Melanoma was most often located on the trunk (33.2%) with a median Breslow thickness of 0.8 mm (IQR 0.5–2.0) and an ulceration rate of 16.8% (Table 1).

Stage grouping and reclassification
Of the 6,414 melanomas in our study, 1,365 (21.3%) received a different stage subgroup upon reclassification from TNM7 to TNM8. Within stages I and II, all movement was to lower stage subgroups: 1,056 from IB to IA, and 11 from IIA/B to a lower stage or subgroup. The remaining reclassifications occurred within the stage III subgroups. Of the 598 stage III melanomas in TNM7, 298 (49.8%) were reclassified in TNM8, 264 (44.1%) of which moved to a higher subgroup. Stage IIIB was the most common subgroup in TNM7 (219 cases; 36.6%) whereas stage IIIC was the most common subgroup in TNM8 (325 cases; 54.3%). Stage IIIC had the highest conservation between TNM7 and TNM8 with 75.8% of 39 TNM8 stage IIID cases were originally TNM7 stage IIIC. Stage IIIB was the most common subgroup in TNM7 (219 cases; 36.6%) whereas stage IIIC was the most common subgroup in TNM8 (325 cases; 54.3%). Stage IIIC had the highest conservation between TNM7 and TNM8 with 75.8% of cases remaining IIIC. Stage IIIB had the lowest conservation, with only 24.7% of cases remaining unchanged. All 39 TNM8 stage IIID cases were originally TNM7 stage IIIC (see Additional file 1).

Melanoma-specific survival
The Kaplan–Meier MSS curves according to the TNM 7th and 8th edition can be found in Figs. 2A and B, respectively. Patients were followed for an average of 4.60 years, with 5,916 patients censored at 5 years for the MSS analysis. Notable changes in MSS between TNM7 and TNM8 were present for stage IB and stages IIIA/B/C disease. Compared to TNM7, TNM8 stage IB experienced a modest decrease in 2-year and 5-year MSS, while...
| Table 1  | Patient and disease characteristics |
|----------|-------------------------------------|
| **Eligible participants** | **6,414** | **Stage at Diagnosis** |
| **Age** | | **TNM7** |
| Median (IQR) | 61 (49–73) | IA 2,634 (41.1%) |
| **Sex** | | IB 1,914 (29.8%) |
| Female | 3,097 (48.3%) | Stage I total 4,548 |
| Male | 3,317 (51.7%) | IIA 529 (8.3%) |
| **Breslow Thickness (mm)** | | IIB 405 (6.3%) |
| Median (IQR) | 0.8 (0.5–2.0) | IIC 280 (4.4%) |
| 0 to < 0.8 | 2,887 (45.0%) | IIIB 219 (3.4%) |
| 0.8 to 1 | 803 (12.5%) | IIIC 207 (3.2%) |
| > 1 to 2 | 1,153 (18.0%) | IIID - |
| > 2 to 4 | 786 (12.3%) | Stage III total 598 |
| > 4 | 732 (11.4%) | IV 54 (0.8%) |
| Missing | 53 (0.8%) | **TNM8** |
| **Location** | | |
| Arm or shoulder | 1,611 (25.1%) | IA 3,692 (57.6%) |
| Head and neck | 1,168 (18.2%) | IB 864 (13.5%) |
| Leg or hip | 1,470 (22.9%) | Stage I total 4,556 |
| Trunk | 2,128 (33.2%) | IIA 524 (8.2%) |
| Other, or missing | 37 (0.6%) | IIB 402 (6.3%) |
| **Ulceration** | | IIC 280 (4.4%) |
| Present | 1,080 (16.8%) | IIIB 219 (3.4%) |
| Absent | 4,899 (76.4%) | IIIC 207 (3.2%) |
| Missing | 435 (6.8%) | IIID - |
| **Histological Subtype** | | **T category** |
| Melanoma, NOS | 2,041 (31.8%) | T1a 2,653 (41.4%) |
| Nodular melanoma | 781 (12.2%) | T1b 1,053 (16.4%) |
| Lentigo maligna melanoma | 441 (6.9%) | T2a 992 (15.5%) |
| Superficial spreading melanoma | 2,684 (41.9%) | T2b 186 (2.9%) |
| Acral lentiginous melanoma | 98 (1.5%) | T3a 459 (7.2%) |
| Other | 369 (5.8%) | T3b 338 (5.3%) |
| **Mitotic rate (per mm²)** | | **TNM7** |
| < 1 | 1,785 (27.8%) | T1a 2,653 (41.4%) |
| ≥ 1 | 3,150 (49.1%) | T1b 1,053 (16.4%) |
| Missing | 1,479 (23.1%) | T2a 992 (15.5%) |
| **Residential Area** | | T2b 186 (2.9%) |
| Urban (RIO < 10) | 3,862 (60.2%) | T3a 459 (7.2%) |
| Suburban (10 ≤ RIO < 40) | 1,809 (28.2%) | T3b 338 (5.3%) |
| Rural (RIO ≥ 40) | 677 (10.6%) | T4a 242 (3.8%) |
| Missing | 66 (1.0%) | T4b 491 (7.7%) |
| **Neighbourhood income quintile** | | **TNM8** |
| 1 (Lowest) | 879 (13.7%) | T1a 2,910 (45.4%) |
| 2 | 1,079 (16.8%) | T1b 833 (13.0%) |
| 3 | 1,248 (19.5%) | T2a 967 (15.1%) |
| 4 | 1,442 (22.5%) | T2b 186 (2.9%) |
| 5 (Highest) | 1,749 (27.3%) | T3a 452 (7.1%) |
| Missing | 17 (0.3%) | T3b 334 (5.2%) |
| **Elixhauser comorbidity index** | | **N category** |
| Mean ± SD | 0.3 ± 0.9 | T4a 241 (3.8%) |
| 0 | 5.34 (83.4%) | T4b 491 (7.7%) |
TNM8 stages IIIA/C experienced a 3–16 percentile point increase in 2-year and 5-year MSS.

Several of the TNM8 Kaplan–Meier curves (Fig. 2B) cross. 2-year and 5-year MSS for stage IIIA was greater than stage IIA, IIB, and IIC. TNM8 stage IIIB also had a 2-year and 5-year MSS greater than stage IIC. MSS decreased for each stage from IA-IIC and from IIIA-IIID (Table 2). Among stage III, there was wide separation of subgroups. Stage IIIA had the best survival followed by IIIB, IIIC, and IIID. The confidence limits for stage IIID and stage IV overlap at the 2-year and 5-year point estimates.
For the OS analysis, the Kaplan–Meier curves followed similar trends, with 5,398 patients censored at 5 years (see Additional file 2). There was an improved 2-year and 5-year OS for TNM8 stage IIIA/B/C compared to TNM7 stage IIIA/B/C. Similarly, the 2-year and 5-year OS for TNM8 stage IIIA was greater than stage IIA, IIB, and IIC. The 2-year and 5-year OS for stage IIID was again overlapping with stage IV (see Additional file 3).

### Cox regression model & hazard ratios

The Cox regression model for the TNM8 staging system demonstrated that hazard ratios (HRs) for stages IA–IIB were lower than the reference (IIC), and HRs for stages IIIC–IV were higher than the reference, indicating a superior and inferior MSS, respectively. The wide spread of HRs suggests that, once adjusted for patient- and disease-characteristics, the TNM8 staging system appropriately separates prognostically distinct subgroups with respect to MSS. Stage IIIA and IIIB were exceptions. In the case of IIIA, the HR was smaller than the IIC reference group (HR 0.28 [95% CI 0.14–0.56]). In the case of IIIB, the HR was similar in magnitude to the reference group (HR 0.86 [95% CI 0.54–1.36]). The HR increased sequentially with each stage from IA–IIC and IIIA–IIID as the MSS declined (Table 3). The introduction of stage IIID led to a reduction in HR for stages IIIA/B/C, with stage IIIC having the largest decrease.

#### Table 2 2-year and 5-year melanoma-specific survival and 95% confidence interval (CI) for each stage of the 7th and 8th edition TNM melanoma staging system

| Stage | TNM7 2-year | 95% CI | TNM8 2-year | 95% CI | TNM7 5-year | 95% CI | TNM8 5-year | 95% CI |
|-------|-------------|--------|-------------|--------|-------------|--------|-------------|--------|
| IA    | 99.9%       | 99.6–100.0% | 99.8%       | 99.6–99.9% | 99.1%       | 98.7–99.3% |
| IB    | 99.2%       | 98.6–99.5% | 98.5%       | 97.4–99.1% | 95.6%       | 94.0–96.8% |
| IIA   | 96.9%       | 95.0–98.1% | 97.1%       | 95.2–98.2% | 90.4%       | 87.5–92.7% |
| IIB   | 92.2%       | 89.1–94.5% | 92.2%       | 89.0–94.5% | 80.8%       | 76.4–84.5% |
| IIC   | 86.6%       | 81.8–90.1% | 86.6%       | 81.8–90.1% | 69.0%       | 62.7–74.4% |
| IIIA  | 94.7%       | 90.1–97.2% | 98.2%       | 93.1–99.6% | 91.7%       | 84.6–95.6% |
| IIIB  | 90.8%       | 86.0–93.9% | 90.9%       | 84.1–94.8% | 74.8%       | 66.0–81.7% |
| IIIC  | 63.0%       | 55.9–69.3% | 79.1%       | 74.2–83.2% | 59.0%       | 53.1–64.3% |
| IIID  | -           | -       | 37.4%       | 22.3–52.4% | 23.5%       | 10.8–39.0% |
| IV    | 39.0%       | 25.7–52.1% | 39.0%       | 25.7–52.1% | 14.4%       | 6.3–25.6% |

#### Table 3 Adjusted cox regression hazard ratios for melanoma-specific survival of each stage of the 7th and 8th edition TNM melanoma staging system

| Stage | TNM7 Hazard Ratio | 95% CI | P-value | TNM8 Hazard Ratio | 95% CI | P-value |
|-------|-------------------|--------|---------|-------------------|--------|---------|
| IA    | 0.03              | (0.02–0.05) | <0.001 | 0.04              | (0.02–0.06) | <0.001 |
| IB    | 0.12              | (0.08–0.18) | <0.001 | 0.17              | (0.11–0.26) | <0.001 |
| IIA   | 0.35              | (0.24–0.51) | <0.001 | 0.33              | (0.22–0.48) | <0.001 |
| IIB   | 0.66              | (0.47–0.93) | 0.019  | 0.66              | (0.46–0.93) | 0.017  |
| IIC   | Reference         | -       | -       | Reference         | -       | -       |
| IIIA  | 0.56              | (0.35–0.91) | 0.020  | 0.28              | (0.14–0.56) | <0.001 |
| IIIB  | 0.94              | (0.65–1.35) | NS     | 0.86              | (0.54–1.36) | NS     |
| IIIC  | 1.95              | (1.35–2.82) | <0.001 | 1.42              | (1.02–1.97) | 0.040  |
| IIID  | -                 | -       | -       | 4.14              | (2.26–7.58) | <0.001 |
| IV    | 6.48              | (4.04–10.37) | <0.001 | 6.57              | (4.08–10.57) | <0.001 |

Adjusted for report/diagnostic year, age, sex, Elixhauser comorbidity index, neighbourhood income quintiles, place of residence, residential area, histological subtype, location, adjuvant/palliative systemic therapy and adjuvant/palliative radiotherapy
Similarly for OS, there was stepwise separation of prognostically distinct subgroups in most cases (see Additional file 4). Stage IIIA had a lower risk of death than the IIC reference group, similar to MSS findings (HR 0.34 [95% CI 0.20–0.58]). As well, the stage IIB and IIC HRs were similar in magnitude to the reference group (HR 0.77 [95% CI 0.52–1.14]; HR 1.19 [95% CI 0.91–1.57]).

Explanation of variance in survival
For TNM8, 19.7% and 17.2% of the variance for the Cox regression for MSS and OS, respectively, is explained by the staging information. For TNM7, the explained variance remains similar at 18.9% and 16.6% for MSS and OS, respectively.

Discussion
Our study set out to investigate the performance of the 8th edition UICC/AJCC TNM (Tumour, Nodes, Metastasis) staging system for cutaneous melanoma using a Canadian population-based sample. We believe our study is the largest population-based validation study to date, with 6,414 eligible participants from stage I-IV. Our study used detailed demographic and disease data from the provincial cancer registry and other administrative sources to estimate overall survival, melanoma-specific survival, and cox regression hazard ratios.

The changes made between TNM7 and TNM8 resulted in the reclassification of many patient’s stage subgroups. Stage IIC was the largest TNM8 stage III subgroup, representing 54.3% of our sample, 48% of the IMDDP, and 41–65% in the literature [6–13]. It is important for providers and patients – in discussion of risks and treatment options – to be aware that stage IIC is now the most common stage III subgroup and has higher survival than reported for TNM7 stage IIC. Notably, the newly introduced stage IIID includes no evidence of distant metastasis, yet the prognosis is poor, and survival is overlapping with stage IV metastatic disease. We found that within stage I, there was substantial movement from IB to IA, due to changes in criteria on thickness, ulceration, and mitosis. However, stages I and II had minimal changes in their 2-year and 5-year MSS. This aligns with the literature reporting little or no changes for stages I and II in 5-year survival [6–10].

Very few patients shifted between the broad stage groups (I, II, III, IV) with 8 moving from stage II to stage I. This highlights that differences in stage subgroup survival relates overwhelmingly to shifts within a given stage’s subgroups (e.g. shifts between TNM7 IIB and TNM8 IIC). Our findings also suggest that historic data staged with TNM7 can be expected to have very similar underlying major disease factors (e.g. thickness, node positivity, presence of distant metastasis) to TNM8 staged patients for broad stage groups. The small improvement in the percent of variance in survival explained by stage is of a similar magnitude to typical observations for other cancer sites. In general, the percent of variance explained is low [21–23].

Survival for melanoma decreases with increasing age, ulceration rate, and male sex. Our median age of 61 (IQR 49–73) aligns with that found in several studies [6, 11, 13]. The sex distribution of our cohort at 51.7% males vs 48.3% females was evenly distributed, and our ulceration rate of 16.84% was lower than several studies (30–50%) [8, 11–13]. However, our study sample is composed of 57.6% TNM8 stage IA; a low ulceration rate is expected and consistent with one other study reporting a 16% ulceration rate and a 60% sample proportion of TNM8 stage IA [7].

While the OCR has an excellent tumour-capture rate, some limitations are present. Ulceration, an important prognostic factor, could not be determined in 6.8% of cases. Moreover, risks of misclassification of cause of death from secondary cancers (not counted in MSS) being related to melanoma metastases, and heterogeneous pathology reporting, all introduce potential sources of error.

We demonstrated lower survival for nearly all stages in comparison to the largely institution-based IMDDP that first established the AJCC8 staging system. Our TNM8 5-year MSS for stage I (98.4%), stage II (82.5%) and stage III (66.4%) was comparable or lower than the 5-year MSS for stage I (98%), stage II (90%), and stage III (77%) reported by Gershenwald et al. using the IMDDP [4].

Our 5-year MSS estimates were lower than the IMDDP for all stage subgroups except IA, IIA, and IID, which contained the IMDDP value in their 95% CI. Our 5-year MSS was lower than the IMDDP for stage IB (95.6% vs 97%), IIA (90.4% vs 94%), IIB (80.8% vs 87%), IIC (69.0% vs 82%), IIIB (74.8% vs 83%), and IIC (59.0% vs 69%) [4]. Other validation studies (population-based and institution-based) of the TNM8 similarly reported a lower survival than the IMDDP for many substages [6, 8–13].

It is not immediately clear why the IMDDP cohort reported higher survival for most stages. The IMDDP analysis used institutional data of 46,000 patients from ten institutions globally. None of these institutions were Canadian, and 15,746 patients (33.5%) were from three institutions in the U.S. [4], where access to healthcare is influenced by private and public health coverage. As no demographic and disease characteristics were included, it is difficult to ascertain the influence of confounding variables. Disparities in the study population (e.g., young age, unbalanced sex ratio, higher SES) or disease features (e.g., decreased ulceration rate, primary tumour location) may have influenced survival estimates. We note that similar
to the IMDDP data, our population-based sample comes predominantly before the adoption of new targeted and immune-based therapies for melanoma. This suggests that differences in use of approved novel targeted therapies and immune-based therapies is less likely to be the primary driver [24]. As such, it is important to recognize that the results from the IMDDP analysis may not be generalizable to Canadian populations, and the institutional dataset may differ from population-based outcomes.

Our findings also emphasize the importance of considering subgroup-specific treatment recommendations, and evaluating novel adjuvant therapies for high-risk stage II patients. We highlight this given that survival for stage III and IV patients is improving with immunotherapies (anti-PD1, anti-CTLA4) and targeted therapies (BRAF inhibitors, MEK inhibitors) [25]. Currently, adjuvant pembrolizumab (anti-PD1), nivolumab (anti-PD1), or combination dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) are recommended for resected stage III melanoma (dependant on BRAF status) [26, 27]. These same therapies, however, are not recommended for resected stage II melanoma. Notably, stage IIIA has a lower risk of death than stage IIC, and stage IIB has a similar risk to stage IIC.

Shifts in stage III subgroups are also notable. The MSS for stage IIC improved between TNM7 and TNM8, and the MSS for stage IIID approximated stage IV metastatic disease. The need for expanded treatment recommendations is clear, and several ongoing phase 3 trials will provide valuable insight (NCT04309409, NCT03553836, NCT04099251). In the future, patients will surely benefit from increased access to innovative therapies and further-refined treatment guidelines.

Conclusion
We investigated the performance of the 8th edition UICC/AJCC TNM melanoma staging system in the largest population-based sample published to date. We found that the staging system performed well, with good separation of stage subgroups and a small improvement in the percent of variance explained compared to TNM7. We note that our MSS was similar to other validation studies, though inferior to the original institution-based sample that drove the development of the TNM8. This difference is important for clinicians to consider when advising their patients on expected stage-based outcomes.

Acknowledgements
This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care. Parts of this material are based on data and information compiled and provided by: MOH, CIHI, CCO, ORG, Statistics Canada and IQVIA Solutions Canada Inc. The analyses, conclusions, opinions and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources, no endorsement is intended or should be inferred. Parts of this material are based on data and/or information compiled and provided by CIHI. However, the analyses, conclusions, opinions and statements expressed in the material are those of the authors, and not necessarily those of CIHI. Parts of this material are based on data and information provided by Ontario Health (OH). The opinions, results, view, and conclusions reported in this paper are those of the authors and do not necessarily reflect those of OH. No endorsement by OH is intended or should be inferred. Parts of this report are based on Ontario Registrar General (ORG) information on deaths, the original source of which is ServiceOntario. The views expressed therein are those of the authors and do not necessarily reflect those of ORG or the Ministry of Government Services. We thank IQVIA Solutions Canada Inc. for use of their Drug Information File. This study also used data adapted from the Statistics Canada Postal Code OM Conversion File, which is based on data licensed from Canada Post Corporation, and/or data adapted from the Ontario Ministry of Health Postal Code Conversion File, which contains data copied under license from Canada Post Corporation and Statistics Canada. This does not constitute an endorsement by Statistics Canada of this product.
Availability of data and materials
The dataset from this study is held securely in coded form at ICES. While legal data sharing agreements between ICES and data providers (e.g., healthcare organizations and government) prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS (email: das@ices.on.ca). The full dataset creation plan and underlying analytic code are available from the authors upon request, understanding that the computer programs may rely upon coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.

Declarations

Ethics approval and consent to participate
This study was performed in accordance with institutional ethical guidelines and the declaration of Helsinki. A waiver of informed consent was granted based on the Personal Health Information Protection Act, Sect. 44(1), with ethics approval by the Queen's University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board (EPID-423–13).

Consent for publication
Not applicable.

Competing interests
TDB reports unrelated advisory board/honorarium for Astra Zeneca, Abbvie, Gilead, Roche, Novartis, Merck, and Bristol Myers Squibb. YA reports unrelated research grants from the Canadian Dermatology Foundation, Sanofi, Pfizer, Leo Pharma, and Novartis and honoraria from the Canadian Society for Allergy and Immunology, Medexus, Janssen, Eli Lilly, Pfizer, UC Biomedical, L'Oreal, Aralez, Bausch and Novartis. The remaining authors have no declarations of competing interest.

Author details
1 School of Medicine, Queen's University, Kingston, ON, Canada. 2 Nuffield Department of Population Health, University of Oxford, Oxford, UK. 3 ICES Queen's, Queen's University, Kingston, ON, Canada. 4 Division of Cancer Care and Epidemiology, Department of Public Health Sciences, Queen's Cancer Research Institute, Queen's University, 10 Stuart Street, 2nd Level, Kingston, ON K7L 3N6, Canada. 5 Division of Dermatology, Department of Medicine, School of Medicine, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada. 6 Department of Oncology, Queen's University, Kingston, ON, Canada.

Received: 1 March 2022   Accepted: 15 June 2022

Published online: 01 July 2022

References
1. Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2019. Toronto: Canadian Cancer Society; 2019. (cancerca/canadian-cancer-statistics-2019-en (accessed 7 June 2021)).
2. Erdmann F, Lortet-Tieulent J, Schüz J, Zeeb H, Greinert R, Breitbart EW, Bray F. International trends in the incidence of malignant melanoma 1953–2008—are recent generations at higher or lower risk? Int J Cancer. 2013;132:385–400.
3. Langley A, Levesque L, Baetz T, Asai Y. Brief Report: Increase in Melanoma Incidence in Ontario. J Cutan Med Surg. 2018;22:476–8.
4. Greisenwald JE, Scoley RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Melanoma Staging: AJCC 8th Edition. CA Cancer J Clin. 2017;67:472–92.
5. Brierley JD. TNM classification of malignant tumours. 8th ed. Chichester: Wiley Blackwell; 2017.
6. Kanaki T, Stangl A, Gutzmier R, Zimmer L, Chorti E, Sucker A, Ugurel S, Hadadusch E, Gräger NS, Satzger I, Schadendorf D, Livingstone E. Impact of American joint committee on cancer stage 8th edition classification on staging and survival of patients with melanoma. Eur J Cancer. 2019;119:18–29.
7. Bajaj S, Donnelly D, Call M, Johannet P, Moran U, Polsky D, Shapiro R, Berman R, Pavlick A, Weber J, Zhong J, Osman I. Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition. JNCI J Natl Cancer Inst. 2020;112(9):djaa008.
8. Tetercz P, Lugowska I, Kosela-Paterczyk H, Ruktowski P. Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage. World J Surg Oncol. 2019;17:129.
9. Fujiwasa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, Noma N, Nakamura Y, Asai J, Kato J, Fujiwara S, Fukushima S, et al. Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system. J Dermatol Sci. 2019;94:284–9.
10. Crocetti E, Stanganeli I, Mancini S, Vattiatto R, Giuliani O, Ravaillot A, Balducci C, Falcini F, Pimpinelli N. Evaluation of the agreement between TNM 7th and 8th in a population-based series of cutaneous melanoma. J Eur Acad Dermatol Venereol. 2019;33:521–4.
11. Isaksen K, Katsanellas D, MiKiver R, Carneiro A, Ny L, Olofsson BR. A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden. Ann Surg Oncol. 2019;26:2839–45.
12. Madu MF, Franke V, Van de Wiel BA, Kloop WMJ, Zöjwiak K, van Houdt WJ, Wouters MWJM, van Akkooi ACJ. External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment? Melanoma Res. 2020;30:185–92.
13. Garbe C, Keim U, Suciu S, Amarat T, Eigentler TK, Gesierich A, Hauschild A, Heinezergling L, Kiecker F, Schadenendorf D, Stadler R, Sunderkotter C, et al. Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. Journal of Clinical Oncology. 2020;38:2543–51.
14. Clarke EA, Marrett LD, Kreiger N. Cancer registration in Ontario: a computer approach. IARC Sci Publ. 1991;95:46–7. (PMID: 1894327).
15. Tran JM, Schwartz R, Fung K, Rochon P, Chan A-W. Comprehensive care for cutaneous melanoma of the Ontario Cancer Registry: validation study using community pathology reports. Cancer Causes Control. 2016;27:137–42.
16. Hanna TP, Baetz T, Xu J, Miao Q, Earle CC, Peng Y, Booth CM, Petrella TM, McKay DR, Nguyen P, Langley H, Eisenhauer E. Mental Health Services Use by Melanoma Patients Receiving Adjuvant Interferon: Association of Pre-treatment Mental Health Care with Early Discontinuation. Curr Oncol. 2017;24:503–12.
17. Hanna TP, Eisenhauer EA, Petrella TM, Baetz T, Booth CM, Earle CC, McKay DR, Peng Y, Tone VA. A Population Study of the Toxicity and Effectiveness of High-Dose Interferon for High-Risk Melanoma. Canadian Institutes of Health Research Funding Decisions Database 2022; Available from: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?appid=3057888&lang=en
18. Mavor ME, Richardson H, Miao Q, Asai J, Hanna TP. Disparities in diagnosis of advanced melanoma a population-based cohort study. CMAJ Open. 2018;6:E502–12.
19. Cox DR, Oakes D. Analysis of survival data. London: Chapman & Hall; 1984.
20. Schenper M, Henderson R. Predictive Accuracy and Explained Variat- nation in Cox Regression. Biometrics. 2000;56:249–55.
21. Groome PA, Schulze K, Boysen M, Hall SF, Mackillop WJ. A comparison of published head and neck stage groupings in carcinomas of the oral cavity. Head Neck. 2001;23:613–24.
22. Groome PA, Schulze KM, Mackillop WJ, Grice B, Goh C, Cummings BJ, Hall SF, Liu F-F, Payne D, Rothwell DM, Waldron JN, Warde PR, et al. A comparison of published head and neck stage groupings in carcinomas of the tonsillar region. Cancer. 2001;92:1484–94.
23. Groome PA, Schulze K, Boysen M, Hall SF, Mackillop WJ, O’ Sullivan B, Irish JC, Warde PR, Schneider KM, Mackenzie RG, Hodgson DI, Hammond JA, et al. A comparison of published head and neck stage groupings in laryngeal cancer using data from two countries. J Clin Epidemiol. 2002;55:533–44.
24. Hanna TP, Nguyen P, Baetz T, Booth CM, Eisenhauer EA. A Population- based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma. CMAJ Oncol. 2018;30:609–17.
25. Pasquali S, Hadjinicolaou AV, Chiarion-Sileni V, Rossi CR, Mocellin S. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2018;2:CD011123.

26. Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami UJ, Weber J, Alluri KC, Agarwala S, Ascierto PA, et al. Systemic Therapy for Melanoma: ASCO Guideline. JCO. 2020;38:3947–70.

27. Longo C, Pampena R, Lallas A, Kyrgidis A, Stratigos A, Peris K, Garbe C, Pellacani G. Adjuvant therapy for cutaneous melanoma: a systematic review and network meta-analysis of new therapies. J Eur Acad Dermatol Venereol. 2020;34:956–66.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.